Weight Loss Jab Users Face Insurance Uncertainty in the UK

Over a million people in the United Kingdom who use weight-loss jabs such as Mounjaro Ozempic and Wegovy may be risking their travel and health insurance due to confusion over how to declare these medications. New research by Consumer Intelligence found that 26 per cent of UK adults surveyed were unclear on how best to classify the use of these drugs when purchasing insurance cover.

The study highlighted that only 24 per cent of respondents believed these medications should be treated as prescribed treatments for health conditions. Another 11 per cent thought they were cosmetic treatments and 10 per cent regarded them as lifestyle aids. This widespread uncertainty could leave many consumers vulnerable to denied claims and unexpected costs in the event of an insurance claim.

Insurers in the UK typically require policyholders to declare any pre-existing medical conditions as well as medication taken to manage them. Failure to disclose this information can render a policy invalid regardless of whether a subsequent claim directly involves the condition in question. Claims being declined remains one of the main reasons for customer complaints to the Financial Ombudsman Service in relation to travel insurance.

With the popularity of GLP1 agonists soaring in the UK over the past year and their approval for use through both NHS and private clinics more people than ever are facing the insurance dilemma. About 1.5 million individuals are estimated to be prescribed these drugs as part of their efforts to treat obesity or diabetes. Some insurers such as Admiral have started addressing the trend by issuing dedicated guidance on their websites urging full disclosure from applicants taking weight-loss jabs.

According to GoCompare travellers who declare a pre-existing condition including the use of weight-loss drugs may find themselves paying significantly higher premiums. The average daily cost for a single-trip policy for someone with a disclosed condition stood at £5 compared to £3 for those with no such disclosures. This general risk pricing covers a range of conditions from mild asthma through to cancer and diabetes but underscores the financial impact for weight-loss medication users.

The Association of British Insurers reminds customers to be transparent with their insurers as accurate disclosures remain crucial to maintaining valid cover. Consumers unsure about what they need to declare are strongly advised to contact their insurance provider directly. The risk of invalidated protection is real and clarity is essential for everyone involved given the growing use of weight-loss medications within the UK.